Can Pneumonia Cause Brain Damage?

Pneumonia can cause brain damage through several overlapping pathways, and the risk extends well beyond the acute illness. Severe pneumonia drives inflammation that crosses into the brain, disrupts the barrier meant to protect it, and in some cases allows bacteria or their toxins to reach neural tissue directly. The consequences range from temporary confusion during the infection to measurable cognitive decline that persists a year or more after hospital discharge.

How Pneumonia Reaches the Brain

The brain is supposed to be shielded from bloodstream infections by the blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels. Severe pneumonia compromises that seal. In mouse models of lung infection, pro-inflammatory molecules produced during pneumonia, including cytokines like IL-1β and TNF-α, caused the junctions between blood-brain barrier cells to loosen and disorganize, significantly reducing barrier function.¹ Once that barrier weakens, inflammatory cells and molecules that should stay in the blood can enter brain tissue and trigger damage.

There is also a more alarming route. Research published in Science Advances found that during severe pneumonia, bacteria from the lungs can physically travel to the brain. Researchers observed impairment of both the lung-blood and brain-blood barriers simultaneously, and when they analyzed the species of bacteria found in brain tissue, the profile closely matched the lung flora, suggesting the brain bacteria had originated in the lungs.² Once bacteria colonize brain tissue, they activate microglia and astrocytes, the brain’s immune and support cells, which launch an inflammatory response that can harm the very neurons they are meant to protect.

When pneumonia progresses to sepsis, the picture gets worse. Sepsis-associated encephalopathy, a form of brain dysfunction driven by systemic infection, has been reported in up to 70% of septic patients. The pathology combines neuroinflammation, oxidative stress, reduced brain metabolism, and ongoing blood-brain barrier breakdown.³ Sepsis also promotes the accumulation of amyloid-β and tau protein in the brain, the same proteins associated with Alzheimer’s disease.⁴

Delirium During Pneumonia

The most visible sign that pneumonia is affecting the brain is delirium: sudden-onset confusion, disorientation, agitation, or reduced awareness. A systematic review and meta-analysis spanning five decades of research found that delirium occurred in about 22% of pneumonia patients across 126 studies. When the analysis was restricted to studies that used rigorous screening tools, the rate jumped to around 40%.⁵ That gap suggests delirium is substantially underdiagnosed in everyday clinical settings.

The same meta-analysis found that delirium during pneumonia was associated with a roughly fourfold increase in the odds of dying. Predisposing factors included older age and pre-existing neurological or systemic conditions. One unexpected finding was that the type of pathogen causing the pneumonia did not significantly affect delirium rates. COVID-19 pneumonia, bacterial pneumonia, and influenza pneumonia all produced similar rates of delirium.⁵ This points to the systemic inflammatory response as the main driver rather than anything unique to a specific bug.

Among older adults specifically, a retrospective analysis of community-acquired pneumonia patients with an average age of 84 found a delirium incidence of about 20%. Higher levels of the inflammatory marker IL-6 and metabolic stress (measured by blood sugar relative to baseline) were independent risk factors, while better nutritional status was protective.⁶ In practical terms, an older person who is poorly nourished and develops pneumonia faces a compounded risk of acute brain dysfunction.

How Pneumococcal Toxins Directly Kill Brain Cells

Some of the brain damage from pneumonia comes not from the body’s inflammatory response but from toxins produced by the bacteria themselves. Streptococcus pneumoniae, the most common bacterial cause of pneumonia, produces a toxin called pneumolysin. This protein punches pores in cell membranes, and lab studies show it can kill brain cells even at concentrations too low to lyse them outright.

Purified pneumolysin induced apoptosis, a form of programmed cell death, in both microglial cells and hippocampal neurons. Researchers confirmed it was the pore-forming activity of the toxin that was lethal: mutant versions of pneumolysin that could not form pores failed to trigger cell death.⁷ A separate study showed that pneumolysin killed neurons through a strong calcium influx driven by the pores themselves, independent of the cell’s normal calcium channels, and the damage was dose- and time-dependent.⁸

Beyond killing individual neurons, pneumolysin wrecks the connections between them. In mouse brain slices exposed to the toxin, researchers observed permanent dendritic swelling, loss of dendritic spines, and destruction of synapses. The mechanism involved glutamate: pneumolysin triggered astrocytes to release glutamate, and the resulting overstimulation of glutamate receptors caused the synaptic damage. Blocking those receptors with antagonist drugs reduced the pathology.⁹ Much of this work comes from meningitis models, where pneumococci are already in the brain, but the bacterial translocation research described earlier shows that severe pneumonia alone can deliver these organisms to brain tissue.

Stroke Risk After Hospitalization for Pneumonia

Pneumonia dramatically increases the short-term risk of stroke and other blood vessel blockages, and this vascular pathway is another route to brain damage. A population-wide study of 2.6 million people in Wales tracked arterial and venous clotting events after hospitalization for respiratory infections. In the first week after a pneumonia or influenza hospitalization, the risk of a first arterial clot (such as a stroke or heart attack) was more than five times higher than baseline. That risk remained roughly doubled through the fourth month and stayed modestly elevated out past a year.¹⁰

The mechanisms behind this are not exotic. Severe infection ramps up coagulation, damages blood vessel linings, and promotes the kind of systemic inflammation that makes existing arterial plaques unstable. For the brain, the practical consequence is that even if pneumonia does not cause direct neuroinflammation in a given patient, it can still lead to brain damage by causing a stroke during or shortly after the illness.

Cognitive Decline That Persists After Recovery

Perhaps the most troubling dimension of pneumonia-related brain effects is what happens after the infection clears. A prospective cohort study followed patients hospitalized for community-acquired pneumonia and found that only about 12% had signs of cognitive impairment before admission. Two months later, 38% showed mild cognitive impairment, and 12 months out, 30% still did. Moderate-to-severe impairment was present in about a third of patients aged 65 and older at the one-year mark and in roughly 20% of younger patients. The deficits clustered around attention, memory, and visuospatial function.¹¹

A large UK matched cohort study reinforced these findings at a population level: people previously hospitalized with pneumonia had 53% higher incidence of cognitive impairment and dementia compared to matched controls. The highest incidence came in the first year after hospitalization, when the risk was 89% higher than in the general population.¹²

Whether pneumonia directly causes dementia or merely accelerates decline in people already on that trajectory is harder to pin down. A longitudinal propensity-matched study found a steeper cognitive decline in the first two and a half years after pneumonia, but the overall dementia hazard ratio was not statistically significant over the full follow-up period.¹³ The picture that emerges is of a transient but meaningful cognitive hit that may tip vulnerable people over the threshold into clinical impairment, even if the infection does not cause ongoing neurodegeneration in everyone.

Why the Brain Stays Vulnerable Even After the Lungs Heal

One reason pneumonia’s brain effects outlast the chest infection involves the gut. Patients with severe pneumonia or acute respiratory distress syndrome (ARDS) often develop disrupted gut bacteria, with a shift toward Gram-negative species that produce endotoxins. In animal experiments, transplanting the gut bacteria from ARDS and pneumonia patients into mice increased circulating endotoxin, increased inflammation throughout the body, weakened the blood-brain barrier, and caused brain inflammation with loss of neurons. The mice showed behavioral dysfunction consistent with cognitive impairment.¹⁴ In other words, the gut changes caused by severe pneumonia can keep feeding brain inflammation long after the original lung infection resolves.

ICU-related factors add another layer. Patients with ARDS face cognitive decline from a cocktail of overlapping insults: the delirium itself, prolonged sedation, mechanical ventilation, sleep disruption, and the systemic inflammation from sepsis. These risk factors often co-occur and amplify each other.¹⁵ Disentangling which fraction of a given patient’s cognitive decline came from the pneumonia itself versus the ICU experience is nearly impossible in practice. For the patient, the distinction hardly matters: the cognitive problems are real regardless of which specific insult produced them.

Even the brain’s basic plumbing gets disrupted during pneumonia. A study measuring blood flow responses in the brain found that during the acute phase of community-acquired pneumonia, the speed at which blood flow adjusted to neural activity was significantly slowed, a phenomenon called neurovascular uncoupling. In patients who went on to deteriorate clinically, this blood flow mismatch was more severe than in those who recovered. The coupling returned to normal after the pneumonia resolved, suggesting this is a temporary vascular stress on the brain rather than a permanent injury, but in the meantime the brain is running on reduced oxygen delivery precisely when it is most under siege.¹⁶

Children Face Distinct Risks

Pneumonia’s brain effects are not limited to older adults. Among more than 4,000 children under five hospitalized with pneumonia in Bangladesh, about 12.5% had seizures. Children with both pneumonia and seizures were far more likely to develop respiratory failure (18% versus 3%) and to die during hospitalization (13% versus 3%). Low oxygen levels, severe pneumonia, severe sepsis, and high sodium levels were all independent risk factors for seizure.¹⁷

Certain pathogens carry outsized neurological risk in children. Mycoplasma pneumoniae, a common cause of “walking pneumonia” in school-age kids, can occasionally trigger encephalitis. In a case series of 17 children with Mycoplasma encephalitis, altered consciousness occurred in 65%, seizures in 41%, and personality or behavior changes in 29%. Most (82%) recovered fully, but 18% had lasting sequelae including epilepsy, hydrocephalus, and global neurological deficits.¹⁸ These complications are rare in the overall population of kids with Mycoplasma infection, but they illustrate that even a pathogen generally considered mild can occasionally hit the brain hard.

A comparison of children hospitalized with seizures alongside respiratory infections found that rates of stroke, encephalopathy, and meningoencephalitis were similar regardless of whether the respiratory infection was SARS-CoV-2, influenza, or another pathogen.¹⁹ As in adults, the systemic inflammatory response seems to matter more than the specific virus or bacterium involved.

Existing Dementia Makes Everything Worse

People who already have dementia face a vicious feedback loop. Dementia increases the risk of aspiration pneumonia (inhaling food or saliva into the lungs), and aspiration pneumonia in turn accelerates cognitive decline. A retrospective cohort analysis found that aspiration pneumonia sped up cognitive deterioration by a clinically meaningful margin in older adults with dementia.²⁰ Each episode of pneumonia chips away at cognitive reserve that these patients cannot afford to lose, and the swallowing difficulties caused by advancing dementia make the next episode more likely.

Pneumococcal Vaccination and Dementia Risk

If pneumonia can damage the brain, preventing pneumonia should logically protect it. The data on pneumococcal vaccination and subsequent dementia risk is striking, though it comes with caveats. A systematic review and meta-analysis found that pneumococcal vaccination was associated with a 36% reduction in Alzheimer’s disease risk across three studies involving roughly 680,000 people.²¹ A separate study using a large US insurance database reported an even larger association, with vaccinated adults aged 65 and older showing a 63% lower risk of Alzheimer’s compared to unvaccinated adults.²²

A Japanese prospective cohort study supported the direction of the finding, though the effect was more modest: pneumococcal vaccination was associated with a 17-23% reduction in incident dementia depending on follow-up length.²³ The range across studies is wide, and all of this evidence is observational. People who get vaccinated tend to be healthier and more engaged with the healthcare system overall, which makes it hard to know how much of the benefit comes from the vaccine itself versus the “healthy user” effect. Still, the consistency of the association across different populations is worth noting, and it fits with the biological plausibility established by the brain-damage mechanisms research.

Experimental Approaches to Preventing Brain Injury During Meningitis

Standard treatment for bacterial meningitis, which shares many mechanisms with severe pneumococcal pneumonia that reaches the brain, involves antibiotics like ceftriaxone. The problem is that these antibiotics work by bursting bacterial cells open, which releases a flood of toxins including pneumolysin all at once. In an experimental model of pediatric pneumococcal meningitis, researchers tested a combination of a non-cell-bursting antibiotic with a drug that blocks certain tissue-destroying enzymes. The combination therapy significantly improved learning and memory in the infected animals and reduced hearing loss compared to standard ceftriaxone treatment alone.²⁴ This work remains in the animal-model stage, but it highlights a genuinely different approach to the problem: instead of just killing the bacteria faster, limit the collateral damage their death causes to brain tissue.